AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00471965
Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Trial: NCT00471965
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
Trial: NCT04132661
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single dose
Trial: NCT01030536
Drug: CAT-8015 20 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Trial: NCT01030536
Drug: CAT-8015 30 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Trial: NCT01030536
Drug: CAT-8015 40 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Trial: NCT01030536
Drug: CAT-8015 50 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Trial: NCT01030536
Drug: CAT-8015 60 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
Trial: NCT00304746
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
Trial: NCT00304746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02261896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate usefullness of antibiotic prophylaxis
Trial: NCT00600925
Drug: gentamicin-collagen sponge dipped in saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 gentamicin-collagen sponges inserted before closure of the laparotomy
Trial: NCT03582332
Drug: Indomethacin SR, 75 Mg Oral Capsule, Extended Release
RxNorm normalized name: Indomethacin SR, 75 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
Trial: NCT03582332
Drug: Indomethacin 25 Mg Oral Capsule
RxNorm normalized name: Indomethacin 25 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
Trial: NCT03582332
Drug: Etoricoxib 90 mg
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg once daily orally
Trial: NCT03582332
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg once daily orally
Trial: NCT02107898
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Trial: NCT01074554
Drug: Antibiotic Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
Trial: NCT02107898
Drug: Lipid-Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Trial: NCT00204737
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01873144
Drug: Epinephrine 1/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
Trial: NCT01873144
Drug: HSS 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
Trial: NCT01431989
Drug: Amoxil® 500mg/5mL powder for oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation
Trial: NCT04423276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Trial: NCT03847246
Drug: Baraclude® tablets,1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral,once,under fasting condition
Trial: NCT00531271
Drug: ABI-008 (nab-docetaxel)
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
Trial: NCT02147470
Drug: Definity ultrasound contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
Trial: NCT00623779
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER formulation
Trial: NCT03345914
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)
Trial: NCT01199861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for oral administration.
Trial: NCT01456611
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Sodium Gel 1%
Trial: NCT01456611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Gel
Trial: NCT04396301
Drug: Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
Trial: NCT00965653
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \>/= 5 mg po weekly
Trial: NCT00965653
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 - 25 mg weekly (oral or parenteral)
Trial: NCT00718679
Drug: IVN201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphativ injection of the study drug
Trial: NCT00718679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02459301
Drug: IPH2201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01951274
Drug: VPD-737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK1 Receptor Antagonist
Trial: NCT01951274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02569658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04020380
Drug: Azithromycin 250Mg Capsule
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg OD
Trial: NCT02222740
Drug: 10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
RxNorm normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Schedule II Class
Trial: NCT02222740
Drug: 20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
RxNorm normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Schedule II Class
Trial: NCT01365052
Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
Trial: NCT01365052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
Trial: NCT00424983
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00796822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill three times a day for 8 weeks
Trial: NCT02126865
Drug: Placebo to BI 1060469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02126865
Drug: BI 1060469 Healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01582347
Drug: Subutex®/Suboxone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.
Trial: NCT01582347
Drug: Placebo for RBP-6300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.
Trial: NCT01582347
Drug: Placebo for Subutex®/Suboxone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
Trial: NCT01426126
Drug: Genexol PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
Trial: NCT02968485
Drug: SHR7390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
Trial: NCT00417209
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered orally from Day 1 to Day 14 q3w
Trial: NCT00766688
Drug: AVE5530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Trial: NCT02750293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00766688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Trial: NCT00845858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes before meals and at bedtime
Trial: NCT01484275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Trial: NCT01809106
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 microg/h
Trial: NCT00508365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match each dose level will be provided.
Trial: NCT01124396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005044
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist of choice. The manufacturer's instructions should be followed.
Trial: NCT04168346
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% infusion
Trial: NCT02381886
Drug: IDH305
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00094302
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
Trial: NCT00094302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of spironolactone
Trial: NCT04226443
Drug: Remifentanil intravenous bolus dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
Trial: NCT02494024
Drug: Single dose C2N-8E12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.
Trial: NCT02494024
Drug: Single dose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
Trial: NCT00537836
Drug: BAY 86-5310 (ZK 283197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
Trial: NCT00537836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily p.o. over 8 weeks
Trial: NCT00537836
Drug: 17ß-estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
Trial: NCT04089982
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01674530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mcg capsules of both experimental Lubiprostone and AMITIZA
Trial: NCT01137786
Drug: Non ionic contrast media comparator
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time administration for PCI
Trial: NCT01137786
Drug: Non ionic contrast media comparator
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one time administration for PCI
Trial: NCT00147238
Drug: Ferumoxtran-10 (USPIO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
Trial: NCT03697590
Drug: No curettage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PDT without curettage
Trial: NCT03697590
Drug: Curettage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PDT
Trial: NCT02412657
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00088855
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03719664
Drug: 3BNC117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3BNC117
Trial: NCT00547495
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
Trial: NCT03093506
Drug: Micro-dose rhEpo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20IU/kg/week
Trial: NCT01052116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03719664
Drug: Baseline ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects continuing on baseline ART
Trial: NCT00063622
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily
Trial: NCT02026297
Drug: Placebo; Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline
Trial: NCT01582451
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01200641
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
Trial: NCT01200641
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
Trial: NCT00844675
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
Trial: NCT00101582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02528396
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at t0,or t+15 minutes or t-15minutes with test meal
Trial: NCT02962388
Drug: IFNα/ PegIFNα
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
Trial: NCT01206348
Drug: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
Trial: NCT01146834
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
Trial: NCT00424203
Drug: AC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00424203
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00424203
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01919190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01739790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
Trial: NCT02240407
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will provide 650 mg of tylenol before each dose of Rituximab.
Trial: NCT02240407
Drug: LMX 4 Topical Cream
RxNorm normalized name: LMX 4 Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia cream will be used prior to gene therapy/saline injection.
Trial: NCT00175357
Drug: Diamorphine hydrochloride
RxNorm normalized name: Diamorphine hydrochloride
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
Trial: NCT01941095
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.